{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:02:36Z","timestamp":1780293756247,"version":"3.54.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cognitive impairment is a clinically significant, non-motor symptom of Parkinson\u2019s disease (PD) commonly associated with reduced quality of life, increased caregiver burden, and higher risk of progression to dementia. Mild cognitive impairment in PD (PD-MCI) is expressed heterogeneously, with likely prognostic implications. This pilot study evaluated the feasibility and preliminary diagnostic performance of a Machine Learning\/Augmented Reality (ML\/AR)-based digital assessment for identifying PD-MCI to compare with clinician-led classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Altoida NeuroMarker (hereafter, \u201cNeuroMarker\u201d) is a 10 min, self-administered digital cognitive and functional assessment performed by tablet, comprised of thirteen task challenges. The NeuroMarker was administered to 21 patients with PD. NeuroMarker-based MCI classification was compared to clinician-led classification using a confusion matrix to compute sensitivity, specificity, PPV, NPV, accuracy, and Cohen\u2019s \u03ba. Clinical assessments included the MMSE, ACE-III, Hoehn and Yahr stage, and BDI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The NeuroMarker identified all six clinician-classified PD-MCI cases and classified an additional 11 patients with likely MCI. Sensitivity was 100% (95% CI: 54.1\u2013100), specificity was 26.7% (95% CI: 7.8\u201355.1), PPV was 35.3% (95% CI: 14.2\u201361.7), NPV was 100% (95% CI: 39.8\u2013100), accuracy was 47.6% (95% CI: 25.7\u201370.2), and \u03ba = 0.17. Group differences were observed for age, ACE-III, sex, and education.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These preliminary findings suggest that the NeuroMarker may identify clinician-recognized PD-MCI cases, with the potential to also flag patients with early or subthreshold cognitive impairment. However, the study\u2019s wide confidence intervals, low agreement, smaller sample size, and absence of longitudinal confirmation limit interpretation. Larger studies utilizing comprehensive neuropsychological assessment and longitudinal follow-up are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1839000","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:26:37Z","timestamp":1780291597000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming the diagnostic gap in mild cognitive impairment in Parkinson\u2019s disease: a pilot study employing a machine learning-\/augmented reality-based digital biomarker"],"prefix":"10.3389","volume":"18","author":[{"given":"Karolina","family":"Poplawska-Domaszewicz","sequence":"first","affiliation":[{"name":"Institute of Neurological Disorders, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Streel","sequence":"additional","affiliation":[{"name":"Altoida Inc.","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Brek","sequence":"additional","affiliation":[{"name":"Institute of Neurological Disorders, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Mi\u015bko","sequence":"additional","affiliation":[{"name":"Institute of Neurological Disorders, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Kosi\u0144ska","sequence":"additional","affiliation":[{"name":"University Hospital","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Metta","sequence":"additional","affiliation":[{"name":"Kings Parkinson\u2019s Centre of Excellence, King\u2019s College Hospital, Dubai Hills","place":["Dubai, United Arab Emirates"]},{"name":"Kings College Hospital","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Lund University","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[{"name":"Neurodegenerative Disease Unit, Department of Neuroscience, Padua Neuroscience Center (PNC), University of Padua","place":["Padua, Italy"]},{"name":"IRCCS San Camillo","place":["Venice, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Biundo","sequence":"additional","affiliation":[{"name":"IRCCS San Camillo","place":["Venice, Italy"]},{"name":"Department of General Psychology, University of Padova","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Fiorenzato","sequence":"additional","affiliation":[{"name":"Neurodegenerative Disease Unit, Department of Neuroscience, Padua Neuroscience Center (PNC), University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kit","family":"Wu","sequence":"additional","affiliation":[{"name":"Kings College Hospital","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saivansh","family":"Chopra","sequence":"additional","affiliation":[{"name":"Kings Parkinson\u2019s Centre of Excellence, King\u2019s College Hospital, Dubai Hills","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikaanth","family":"Haridas","sequence":"additional","affiliation":[{"name":"Kings Parkinson\u2019s Centre of Excellence, King\u2019s College Hospital, Dubai Hills","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tarnanas","sequence":"additional","affiliation":[{"name":"Altoida Inc.","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Griffin","sequence":"additional","affiliation":[{"name":"Altoida Inc.","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Brugada-Ramentol","sequence":"additional","affiliation":[{"name":"Altoida Inc.","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Florencia","family":"Iulita","sequence":"additional","affiliation":[{"name":"Altoida Inc.","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Jones","sequence":"additional","affiliation":[{"name":"Altoida Inc.","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Michalak","sequence":"additional","affiliation":[{"name":"Institute of Neurological Disorders, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Kozubski","sequence":"additional","affiliation":[{"name":"Institute of Neurological Disorders, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallol","family":"Ray Chaudhuri","sequence":"additional","affiliation":[{"name":"Kings Parkinson\u2019s Centre of Excellence, King\u2019s College Hospital, Dubai Hills","place":["Dubai, United Arab Emirates"]},{"name":"Dementech Neuroscience Clinical Academic Centre","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment.","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.27902","article-title":"Prevalence and clinical aspects of mild cognitive impairment in Parkinson\u2019s disease: A meta-analysis.","volume":"35","author":"Baiano","year":"2020","journal-title":"Mov. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/mds.30166","article-title":"Neuropsychological tests of memory, visuospatial, and language function in Parkinson\u2019s disease: Review, critique, and recommendations.","volume":"40","author":"Bezdicek","year":"2025","journal-title":"Mov. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/mds.30293","article-title":"Attention\/Working memory and executive function in Parkinson\u2019s disease: Review, critique, and recommendations.","volume":"40","author":"Biundo","year":"2025","journal-title":"Mov. Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e12073","DOI":"10.1002\/dad2.12073","article-title":"Digital biomarker-based individualized prognosis for people at risk of dementia.","volume":"12","author":"Buegler","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B6","doi-asserted-by":"publisher","first-page":"123617","DOI":"10.1016\/j.jns.2025.123617","article-title":"The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer\u2019s disease and frontotemporal dementia.","volume":"476","author":"Campagnolo","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.parkreldis.2018.02.007","article-title":"Sex differences in progression to mild cognitive impairment and dementia in Parkinson\u2019s disease.","volume":"50","author":"Cholerton","year":"2018","journal-title":"Parkinson. Relat. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ejn.14094","article-title":"The clinical heterogeneity of PD and its therapeutic implications.","volume":"49","author":"Greenland","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1495975","DOI":"10.3389\/fnins.2024.1495975","article-title":"study on the exploration of mild cognitive impairment in Parkinson\u2019s disease based on decision-making cognitive computing.","volume":"18","author":"Huang","year":"2025","journal-title":"Front. Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1007\/s13311-020-00894-7","article-title":"Therapy of Parkinson\u2019s disease subtypes.","volume":"17","author":"Marras","year":"2020","journal-title":"Neurotherapeutics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s00415-018-8800-4","article-title":"Mild cognitive impairment in Parkinson\u2019s disease: The Parkinson\u2019s disease cognitive study (PACOS).","volume":"265","author":"Monastero","year":"2018","journal-title":"J. Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41746-023-00978-6","article-title":"Augmented reality versus standard tests to assess cognition and function in early Alzheimer\u2019s disease.","volume":"6","author":"Muurling","year":"2023","journal-title":"NPJ Digit. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"108072","DOI":"10.1016\/j.parkreldis.2025.108072","article-title":"Parkinson\u2019s disease mild cognitive impairment with MRI evidence of cholinergic nucleus 4 degeneration: A new subtype?","volume":"141","author":"Negida","year":"2025","journal-title":"Parkinson. Relat. Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/wnl.0000000000003634","article-title":"Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study.","volume":"88","author":"Pedersen","year":"2017","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B16","article-title":"Pilot feasibility data using augmented reality and machine learning-based digital cognitive assessment in Parkinson\u2019s disease [abstract].","volume":"40","author":"Poplawska-Domaszewicz","year":"2025","journal-title":"Mov. Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"107123","DOI":"10.1016\/j.parkreldis.2024.107123","article-title":"Recognition and characterising non-motor profile in Early Onset Parkinson\u2019s Disease (EOPD).","volume":"129","author":"Poplawska-Domaszewicz","year":"2024","journal-title":"Park Rel. Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1174698","DOI":"10.3389\/fneur.2023.1174698","article-title":"Chaudhuri\u2019s dashboard of vitals in Parkinson\u2019s syndrome: An unmet need underpinned by real life clinical tests.","volume":"14","author":"Qamar","year":"2023","journal-title":"Front. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","article-title":"Parkinson disease therapy: Current strategies and future research priorities.","volume":"20","author":"Stocchi","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.dadm.2015.10.005","article-title":"Five-year biomarker progression variability for Alzheimer\u2019s disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?","volume":"1","author":"Tarnanas","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/brain\/awp245","article-title":"The distinct cognitive syndromes of Parkinson\u2019s disease: 5 year follow-up of the CamPaIGN cohort.","volume":"132","author":"Williams-Gray","year":"2009","journal-title":"Brain"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15027","DOI":"10.1038\/npjparkd.2015.27","article-title":"Different PD-MCI criteria and risk of dementia in Parkinson\u2019s disease: 4-year longitudinal study.","volume":"2","author":"Wood","year":"2016","journal-title":"NPJ Parkins. Dis."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1839000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:26:38Z","timestamp":1780291598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1839000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":23,"alternative-id":["10.3389\/fnagi.2026.1839000"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1839000","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1839000"}}